Cancer_Health_Outcomes_and_Control_Research_Program

Grant to develop ways to measure medical mistrust in African-American men

Read more about Grant to develop ways to measure medical mistrust in African-American men

Vanderbilt University Medical Center has been awarded a two-year, $250,000 grant by The Robert Wood Johnson Foundation to develop new ways to measure trust in African-American men as it relates to health care.

Wilkins takes key role in national ‘All of Us’ precision medicine effort

Read more about Wilkins takes key role in national ‘All of Us’ precision medicine effort

Consuelo Wilkins, MD, MSCI, has been appointed director of a new Engagement Core to support the design, implementation and governance of the national All of Us Research Program, an ambitious effort led by the National Institutes of Health (NIH) to accelerate the prevention and treatment of illness through precision medicine.

Program News

September 3, 2021

Winkfield to direct Meharry-Vanderbilt Alliance

Karen Winkfield, MD, PhD, associate professor of Radiation Oncology at Wake Forest University, associate director for Community Outreach and Engagement, and director of the Office of Cancer Health Equity at Wake Forest Baptist Comprehensive Cancer Center, has been named the new executive director of the Meharry-Vanderbilt Alliance.

April 9, 2020

Study tracks genomics of lung tumor behavior

A study by Vanderbilt researchers has identified genomic alterations in early stage adenocarcinomas of the lung that may indicate whether the lesions develop into aggressive tumors.

May 7, 2020

Study finds AI can categorize cancer risk of lung nodules

Computed tomography scans for people at risk for lung cancer lead to earlier diagnoses and improve survival rates, but they can also lead to overtreatment when suspicious nodules turn out to be benign.

More Program News

New prostate cancer therapy investigated at VUMC

Read more about New prostate cancer therapy investigated at VUMC

Vanderbilt University Medical Center is the world’s first site to treat a patient in the TULSA-PRO Ablation Clinical Trial (TACT), which employs an emerging therapy that uses MRI guidance and robotically driven therapeutic ultrasound to obtain precise prostate cancer tissue ablation. Investigators, David Penson, M.D.

Subscribe to Cancer_Health_Outcomes_and_Control_Research_Program